ArticleSchizophrenia research and treatment2012
Long-acting injectable antipsychotics in first-episode schizophrenia.
Article in Schizophrenia research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study.Therapeutic advances in psychopharmacology · 2022Article
- Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.JAMA network open · 2021Article
- Guidance on the clinical understanding and use of long-acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements.CNS neuroscience & therapeutics · 2021Review
- Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.Early intervention in psychiatry · 2016Review
- Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.CNS drugs · 2016Review
- Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.Expert opinion on pharmacotherapy · 2016Article
- Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.Clinical drug investigation · 2016Article
- Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics.Neuropsychiatric disease and treatment · 2016Article
- Two cases of long-acting paliperidone in adolescence.Therapeutic advances in psychopharmacology · 2015Review
- Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review.Patient preference and adherence · 2015Review
- The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Therapeutic advances in psychopharmacology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.